0000000000613961

AUTHOR

E. Derhovanessian

showing 3 related works from this author

A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunothera…

2017

0301 basic medicineMessenger RNAbusiness.industrymedicine.medical_treatmentMelanomaHematologyFirst in humanImmunotherapymedicine.diseaseClinical trial03 medical and health sciences030104 developmental biology0302 clinical medicinePhase i iiOncologyAntigen030220 oncology & carcinogenesisCancer researchmedicinebusinessLipoplexAnnals of Oncology
researchProduct

IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

2017

0301 basic medicinebusiness.industryMelanomaMutantPhases of clinical researchHematologyFirst in humanmedicine.disease03 medical and health sciences030104 developmental biologyOncologyCancer researchMedicinebusinessAnnals of Oncology
researchProduct

88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast canc…

2020

Oncologymedicine.medical_specialtymedicine.anatomical_structureOncologybusiness.industryInternal medicineT cellmedicineHematologyNeo adjuvantbusinessTriple-negative breast cancerImmune therapyAnnals of Oncology
researchProduct